Shots:
- The EC has approved Sanofi‘s Wayrilz for adults with Immune Thrombocytopenia (ITP) who are refractory to other treatments
- Approval was based on P-III (LUNA 3) trial assessing Wayrilz (400mg, BID, PO) vs PBO in adults (n=202) with ITP over 12wks., after which 64% vs 32% achieved a durable platelet count continued for 24wks., followed by 28wk. OLE & 4wk. safety follow-up; the study is ongoing in adolescents
- Trial met its 1 & 2EPs, showing sustained platelet response at 25wks. (23% vs 0%), faster onset (36 days vs not reached), & longer duration (7 vs 0.7wks.). Pts also achieved a 10.6-point QoL improvement vs 2.3 per ITP Patient Assessment Questionnaire; data were presented at ASH’24 & published in The Blood
Ref: Sanofi | Image: Sanofi | Press Release
Related News: Sanofi to Acquire Dynavax for ~$2.2B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
